PUR Biologics (ORHB) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $3M

Market Cap: $85KFounded: 2018HQ: Cambridge, United States

Sector Ranking#210 in Biologics / Biosimilars #43 in Regenerative Medicine

Overview

PUR Biologics is a clinical-stage biotechnology company developing next-generation biologic products for the multi-billion-dollar orthopedic and spinal regenerative medicine markets. Founded in 2018, the company's strategy is built on a diversified platform of human tissue allografts, synthetic scaffolds, and cellular/amniotic technologies aimed at promoting bone growth, cartilage repair, and disc regeneration. As a key subsidiary of the publicly traded entity HippoFi (ORHB), PUR Biologics aims to commercialize advanced delivery systems like Active Orb and Vital-Mobile while progressing its pipeline toward addressing significant unmet needs in joint preservation and spinal health.

OrthopedicsSpine

Technology Platform

A multi-modal platform integrating Advanced Allografts, Specialized Synthetic scaffolds, and Cellular/Amniotic-ECM technologies, supported by intelligent automation for processing and delivery, aimed at musculoskeletal repair and regeneration.

Funding History

1

Total raised:$3M

Seed$3MUndisclosedApr 15, 2021

Opportunities

The company operates in the large and growing orthopedic biologics market, with a near-term opportunity to capture share with its allograft and synthetic portfolios.

Its long-term, high-value opportunity lies in developing first-in-class regenerative therapies for osteoarthritis and degenerative disc disease, areas with massive unmet need and limited competition.

Risk Factors

Key risks include financial dependence on its micro-cap parent company (ORHB), intense competition from large medtech firms in core markets, and the high technical and regulatory uncertainty associated with its ambitious cartilage and disc regeneration R&D programs.

Competitive Landscape

PUR Biologics faces intense competition from large, integrated medical device companies (e.g., Medtronic, Stryker) with vast resources and from specialized biologics firms. Its differentiation strategy relies on a multi-product portfolio and a focus on intelligent manufacturing automation, but commercial execution against entrenched players is a significant challenge.